Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck, Schering-Plough Dodge Vytorin Enforcement Bullet

This article was originally published in The Pink Sheet Daily

Executive Summary

In settlement with state attorneys general, the companies agree to pay $5.4 million to cover investigative costs and recommit to routine oversight policies.

You may also be interested in...



Merck’s Vytorin Litigation Saga Ends With $688 Million Securities Class Action Settlements

Investors alleged they lost money from the nearly two-year delay in release of results of the Enhance trial; Merck and Schering previously paid $5.4 million to states to resolve Enhance investigation.

FDA's DTC Review Problems Highlight Industry's Growing Legal Squeeze

The Government Accountability Office's report on FDA's staffing and budgeting problems highlights the agency's funding challenge: it's so strapped that it often can't even effectively assess how it's using its resources

FDA's DTC Review Problems Highlight Industry's Growing Legal Squeeze

The Government Accountability Office's report on FDA's staffing and budgeting problems highlights the agency's funding challenge: it's so strapped that it often can't even effectively assess how it's using its resources

Topics

UsernamePublicRestriction

Register

PS069701

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel